• Almeida L, Soares-da-Silva P. (2003) Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs in R&D 4:269284.
  • Almeida L, Soares-da-Silva P. (2004) Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. Journal of Clinical Pharmacology 44: 906918.
  • Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. (2005a) Single dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. Journal of Clinical Pharmacology 45:10621066.
  • Almeida L, Maia J, Soares-da-Silva P. (2005b) A double-blind, add-on, placebo controlled exploratory trail of eslicarbazepine acetate in patients with partial-onset seizures. Epilepsia 46(suppl 8):167168.
  • Ambrosio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM. (2001) Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochemical Pharmacology 61:12711275.
  • Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. (2002) Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochemical Research 27:121130.
  • Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, Cunha RA, Garrett J, Soares-da-Silva P. (1999) Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. Journal of Medicinal Chemistry 42:25822587.
  • Bialer M, Johannessen S, Kupferberg Levy R, Loiseau P, Perucca E. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh EILAT Conference (EILAT VII). Epilepsy Research 61:148.
  • Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. (2001) Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 4:600608.
  • Burneo GB, Montori VM, Faught E. (2002) Magnitude of placebo effect in randomized trials of antiepileptic agents. Epilepsy Behavior 3:532534.
  • Fontes-Ribeiro C, Nunes T, Falcão A, Neta C, Lima R, Tavares S, Almeida L, Macedo T, Soares-da-Silva P. (2005) Eslicarbazepine acetate (BIA 2-093): relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200 mg and 800 mg tablet formulations. Drugs in R&D 6:253260.
  • Hainzl D, Parada A, Soares-da-Silva P. (2001) Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(–)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Research 44:197206.
  • Kuz GM, Manssourian A. (2005) Carbamazepine-induced hyponatremia: assessment of risk factors. Annals of Pharmacotherapy 39:19431946.
  • Maia J, Vaz-da-Silva M, Almeida L, Falcão A, Silveira P, Guimarães S, Graziela P, Soares-da-Silva P. (2005) Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs in R&D 6:201206.
  • Niklson I, Edrich P, Verdru P. (2006) Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures. Epilepsy Research 8:3744.
  • Schmidt D, Sachdeo R. (2000) Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behavior 1:396405.
  • Silveira P, Falcão A, Almeida L, Maia J, Soares-da-Silva P. (2004) BIA 2-093 pharmacokinetics in healthy elderly subjects (abstract). Epilepsia 45(suppl 3):157.
  • Vaz-da-Silva M, Nunes T, Soares E, Rocha JF, Tavares S, Falcão A, Almeida L, Soares-da-Silva P. (2005) Eslicarbazepine acetate pharmacokinetics after single and repeated doses in healthy subjects (abstract). Epilepsia 46(suppl 8):191.